TOP TEN perturbations for Q9GZP4 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9GZP4
Selected probe(set): 223124_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9GZP4 (223124_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

immunoglobulin (IVIG) study 1 (responder) / Kawasaki disease study 1

Relative Expression (log2-ratio):2.834446
Number of Samples:6 / 4
Experimental immunoglobulin (IVIG) study 1 (responder)
Whole blood samples from subjects with Kawasaki disease treated with intravenous immunoglobulin therapy (IVIG; 2g/kg). The IVIG were infused over 24 hours as initial therapy between illness days 2 and 6 (median 5.5). The blood samples were obtained 36 hours after the end of intravenous application of immunoglobulins. Patients had good response to the therapy. ATC code:---
Control Kawasaki disease study 1
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy between illness days 2 and 6 (median 5.5). The subjects showed later positive response to intravenous immunoglobulin therapy (IVIG; 2g/kg).

sickle cell disease study 2 (Pax) / normal blood sample

Relative Expression (log2-ratio):2.6357384
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Pax)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene? Blood RNA System Kit followed by an on-column DNase digestion step.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.

immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)

Relative Expression (log2-ratio):2.4901419
Number of Samples:4 / 4
Experimental immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

sickle cell disease study 2 (Globin red.) / normal blood sample

Relative Expression (log2-ratio):2.326128
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Globin red.)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene? Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear?-Human kit.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit.

azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):2.1255512
Number of Samples:2 / 19
Experimental azathioprine study 8 (48h)
HepG2 cells exposed to 250?M azathioprine in DMSO solvent for 48 hours. ATC code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-1.8468494
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

immunoglobulin (IVIG) study 2 (non-responder) / Kawasaki disease study 2 (non-responder)

Relative Expression (log2-ratio):1.8318014
Number of Samples:6 / 10
Experimental immunoglobulin (IVIG) study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.8012848
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):-1.7591276
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 ? 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

methylprednisolone; immunoglobulin (IVIG) study 1 / Kawasaki disease study 2 (non-responder)

Relative Expression (log2-ratio):1.6442223
Number of Samples:4 / 10
Experimental methylprednisolone; immunoglobulin (IVIG) study 1
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after combined treatment with intravenous methylprednisolone (30mg/kg/2h) followed by intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to simple IVIG therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients exhibited good response to the combined therapy. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:, ,
Control Kawasaki disease study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.